A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now ...

Two patients with congenital generalized lipodystrophy type 1 due to a variant in AGPAT2 (c.589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Rifampin-resistant tuberculosis has traditionally been treated with 18-to-24-month regimens, but shorter, all-oral regimens may offer efficacious alternatives. New research findings are summarized ...

For decades after the identification of mpox in humans in the Democratic Republic of Congo (DRC) in 1970, the disease was largely confined to the rural areas of Central and West Africa and thus ...

Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss. New research findings of its effect on ...

This letter reports an association between acquired osteomalacia and autoantibodies against PHEX (phosphate-regulating endopeptidase X-linked), which may be termed autoimmune osteomalacia.

Whether patients should continue or interrupt oral anticoagulation during transcatheter aortic-valve implantation has been unclear. New research findings are summarized in a short video.

This feature about a child unvaccinated against measles, mumps, and rubella offers a case vignette accompanied by two essays, one supporting accepting the child as a patient without mandating the ...

Mpox has been endemic in remote, rural areas of Africa for decades but has attracted relatively little attention until the global outbreak that began in 2022. In July of that year, I declared a ...